Nasdaq

Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

ERAS-007 100 mg BID-QW + encorafenib + cetuximab (EC) in EC-naïve patients with BRAFm CRC showed a 50% (3/6) response rate (2 cPR, 1 uPR), reinforcing ERAS-007 as a potential best-in-class ERK ...
Nasdaq

Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway

SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for ...
Becker's Hospital Review

Athena Lendvay, ERAS Program Coordinator at El Camino Hospital on the Impact of Adding Enhanced Recovery After Surgery to Hospitals

This episode features Athena Lendvay, the ERAS Program Coordinator at El Camino Hospital. Here, she discusses how El Camino Hospital got started with their ERAS program and the impact it has had on ...
News Medical

ERAS programs help patients better prepare for surgery and recover faster, studies reveal

Enhanced recovery after surgery (ERAS) programs, an important component of the Perioperative Surgical Home (PSH), are helping patients better prepare for surgery and recuperate faster afterward, ...
EurekAlert!

University Hospitals one of fewer than 10 sites nationwide to earn designation as Qualified Center for Enhanced Recovery After Surgery

CLEVELAND -- The colorectal surgery service line at University Hospitals was recently certified as a Qualified Center for Enhanced Recovery After Surgery (ERAS) by the ERAS® Society at the fifth ...